These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16631437)

  • 1. Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus.
    Friedberg SJ; Lam YW; Blum JJ; Gregerman RI
    Metabolism; 2006 May; 55(5):614-9. PubMed ID: 16631437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of breakfast meal composition on second meal metabolic responses in adults with Type 2 diabetes mellitus.
    Clark CA; Gardiner J; McBurney MI; Anderson S; Weatherspoon LJ; Henry DN; Hord NG
    Eur J Clin Nutr; 2006 Sep; 60(9):1122-9. PubMed ID: 16670695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
    Rolla A
    Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biokinetics of buccal spray insulin in patients with type 1 diabetes.
    Pozzilli P; Manfrini S; Costanza F; Coppolino G; Cavallo MG; Fioriti E; Modi P
    Metabolism; 2005 Jul; 54(7):930-4. PubMed ID: 15988703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients.
    Hwang YC; Lee EY; Lee WJ; Cha BS; Yoon KH; Park KS; Lee MK
    Metabolism; 2008 Apr; 57(4):479-87. PubMed ID: 18328348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled insulin--does it become reality?
    Siekmeier R; Scheuch G
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 6():81-113. PubMed ID: 19218634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
    Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
    Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In search of the subcutaneous-insulin-resistance syndrome.
    Schade DS; Duckworth WC
    N Engl J Med; 1986 Jul; 315(3):147-53. PubMed ID: 3523242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.
    Mustad VA; Demichele S; Huang YS; Mika A; Lubbers N; Berthiaume N; Polakowski J; Zinker B
    Metabolism; 2006 Oct; 55(10):1365-74. PubMed ID: 16979408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
    Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
    Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.
    Schütt M; Kern W; Krause U; Busch P; Dapp A; Grziwotz R; Mayer I; Rosenbauer J; Wagner C; Zimmermann A; Kerner W; Holl RW;
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):384-8. PubMed ID: 16915542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.